Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma

NCT07705308 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07705308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07705308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
May 1, 2031
Enrollment
140 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma of the mucosa associated lymphoid tissue (malt)